CureDuchenne is investing $1 million in Entos Pharmaceuticals to support the development of a new DMD gene therapy.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Wilson's new company, Philadelphia-based Gemma Biotherapeutics, plans to start testing gene therapies in Brazil this year.

Kopcho’s spoke on this topic at the AAPS National Biotechnology Conference 2025, which is happening May 4–7, 2025 in Boston. His presentation, “Accelerate Development of AAV-based Gene Therapies with ...

I know firsthand how a misaligned gene vector can lead to ineffective therapies, just as misallocated business resources result in inefficiencies and missed opportunities. In both biotech and ...

PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in January 2025 to evaluate a combination of Versamune MUC1 ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

In 2024, Vector Laboratories merged with Absolute Biotech, expanding its manufacturing and distribution footprint from multiple manufacturing sites in the US to the UK and Europe. Absolute Biotech ...

Explore the wonders of cellular biology with our animated biotechnology icons Covering key concepts such as dna sequencing, gene editing and cell culture, our collection covers all aspects of the ...

“The merger will integrate Absolute Biotech’s validated, off-the-shelf and custom antibodies with Vector’s best-in-class detection and visualization reagents to provide an array of protein ...

Genetically engineered mosquitoes have been released in the tiny East African country of Djibouti to combat a surge in malaria infections caused by an invasive vector. The mosquito species has ...